Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$27.80 +8.3%	$18.28	$9.57 ▼ $27.86	$3.05B	1	2.42 million shs	5.34 million shs
MIRM Mirum Pharmaceuticals	$74.61 +0.4%	$58.58	$36.86 ▼ $76.02	$3.71B	0.92	952,385 shs	622,165 shs
OGN Organon & Co.	$9.80 +4.1%	$9.59	$8.01 ▼ $22.42	$2.45B	0.6	4.44 million shs	3.93 million shs
ZVRA Zevra Therapeutics	$8.92 -2.0%	$10.58	$6.19 ▼ $13.16	$509.14M	1.56	1.62 million shs	881,906 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+8.26%	+27.58%	+68.79%	+68.89%	+21.34%
MIRM Mirum Pharmaceuticals	+0.36%	-0.05%	+42.82%	+67.10%	+80.61%
OGN Organon & Co.	+4.24%	+6.51%	+1.28%	+6.80%	-55.60%
ZVRA Zevra Therapeutics	-1.98%	-4.70%	-20.71%	+1.02%	+22.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	4.2054 of 5 stars	4.5	1.0	0.0	3.4	2.8	2.5	0.0
MIRM Mirum Pharmaceuticals	3.4401 of 5 stars	2.6	0.0	0.0	4.2	3.0	2.5	0.6
OGN Organon & Co.	4.8001 of 5 stars	3.3	3.0	1.7	3.7	2.2	1.7	3.1
ZVRA Zevra Therapeutics	3.094 of 5 stars	4.4	1.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	55.19% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$74.13	-0.65% Downside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	83.60% Upside
ZVRA Zevra Therapeutics	2.89	Moderate Buy	$23.71	165.86% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, MIRM, OGN, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
8/18/2025	ZVRA Zevra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $18.00
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/11/2025	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$89.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
8/8/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $89.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
8/7/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Outperform ➝ Market Outperform	$79.00 ➝ $81.00

(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	1,082.71	N/A	N/A	$3.76 per share	7.39
MIRM Mirum Pharmaceuticals	$336.89M	11.13	N/A	N/A	$5.08 per share	14.69
OGN Organon & Co.	$6.40B	0.40	$5.13 per share	1.91	$2.82 per share	3.48
ZVRA Zevra Therapeutics	$23.61M	21.21	N/A	N/A	$2.09 per share	4.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.21	N/A	N/A	N/A	-13.65%	-24.76%	-8.50%	11/11/2025 (Estimated)
OGN Organon & Co.	$864M	$2.69	3.64	2.62	0.86	11.15%	163.88%	6.99%	10/30/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$0.21	N/A	44.60	N/A	4.33%	-112.40%	-37.67%	11/11/2025 (Estimated)

Latest ZVRA, MIRM, OGN, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	-$0.12	+$0.19	-$0.12	$107.91 million	$127.79 million
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.82%	N/A	2.97%	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest ZVRA, MIRM, OGN, and ARWR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/5/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
MIRM Mirum Pharmaceuticals	1.21	3.13	2.97
OGN Organon & Co.	11.98	1.65	1.13
ZVRA Zevra Therapeutics	0.52	7.85	7.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
MIRM Mirum Pharmaceuticals	N/A
OGN Organon & Co.	77.43%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
MIRM Mirum Pharmaceuticals	22.87%
OGN Organon & Co.	1.40%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
MIRM Mirum Pharmaceuticals	140	50.24 million	38.75 million	Optionable
OGN Organon & Co.	4,000	259.97 million	256.33 million	Not Optionable
ZVRA Zevra Therapeutics	20	56.13 million	54.79 million	Optionable

ZVRA, MIRM, OGN, and ARWR Headlines

Recent News About These Companies

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Moderate Buy" by Brokerages

36 minutes ago | marketbeat.com

Zevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLC

September 3 at 7:06 AM | marketbeat.com

Retirement Planning Co of New England Inc. Has $4.12 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA

September 2 at 8:11 AM | marketbeat.com

Wellington Management Group LLP Purchases New Shares in Zevra Therapeutics, Inc. $ZVRA

September 2 at 3:58 AM | marketbeat.com

Velan Capital Investment Management LP Increases Stake in Zevra Therapeutics, Inc. $ZVRA

August 31, 2025 | marketbeat.com

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

August 28, 2025 | globenewswire.com

Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC

August 26, 2025 | marketbeat.com

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

August 26, 2025 | globenewswire.com

Zacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to Hold

August 22, 2025 | marketbeat.com

Zevra Therapeutics rumor highlighted in Betaville blog

August 21, 2025 | msn.com

Zevra Therapeutics gains amid takeover speculation

August 21, 2025 | msn.com

Zevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 Shares

August 21, 2025 | insidertrades.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Lower Earnings Estimates for ZVRA

August 17, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZVRA Q3 Earnings

August 17, 2025 | marketbeat.com

Q3 EPS Forecast for Zevra Therapeutics Increased by Analyst

August 17, 2025 | marketbeat.com

HC Wainwright Has Bearish Estimate for ZVRA FY2027 Earnings

August 16, 2025 | marketbeat.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

August 15, 2025 | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down on Analyst Downgrade

August 15, 2025 | marketbeat.com

JMP Securities Lowers Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

August 15, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

August 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZVRA, MIRM, OGN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$27.80 +2.12 (+8.26%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$27.91 +0.11 (+0.40%)

As of 09/3/2025 07:48 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$74.61 +0.27 (+0.36%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$74.52 -0.09 (-0.12%)

As of 09/3/2025 07:16 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organon & Co. NYSE:OGN

$9.80 +0.38 (+4.08%)

Closing price 09/3/2025 03:59 PM Eastern

Extended Trading

$9.79 -0.01 (-0.14%)

As of 09/3/2025 06:58 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Zevra Therapeutics NASDAQ:ZVRA

$8.92 -0.18 (-1.98%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$9.16 +0.24 (+2.69%)

As of 09/3/2025 07:59 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time